These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38777770)

  • 1. Comparison of Efficacy between Pemafibrate and Omega-3-Acid Ethyl Ester in the Liver: the PORTRAIT Study.
    Sumida Y; Toyoda H; Yasuda S; Kimoto S; Sakamoto K; Nakade Y; Ito K; Osonoi T; Yoneda M
    J Atheroscler Thromb; 2024 May; ():. PubMed ID: 38777770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study.
    Ono H; Atsukawa M; Tsubota A; Arai T; Suzuki K; Higashi T; Kitamura M; Shioda-Koyano K; Kawano T; Yoshida Y; Okubo T; Hayama K; Itokawa N; Kondo C; Nagao M; Iwabu M; Iwakiri K
    JGH Open; 2024 Apr; 8(4):e13057. PubMed ID: 38572327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effects of pemafibrate on metabolic dysfunction-associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis-4 index and the magnetic resonance imaging-aspartate aminotransferase score.
    Ichikawa T; Oba H; Owada M; Watanabe K; Yoshimura T; Fuchigami A; Nakamura A
    JGH Open; 2023 Dec; 7(12):959-965. PubMed ID: 38162848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study).
    Takeda Y; Sakuma I; Hiramitsu S; Okada M; Ueda S; Sakurai M
    Front Cardiovasc Med; 2023; 10():1094100. PubMed ID: 36760560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption.
    Iwasa M; Sugimoto R; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):793-801. PubMed ID: 38526942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study.
    Morishita A; Oura K; Takuma K; Nakahara M; Tadokoro T; Fujita K; Tani J; Shi T; Himoto T; Tatsuta M; Moriya A; Senoo T; Tsutsui A; Nagano T; Takaguchi K; Ono M; Masaki T
    Hepatol Int; 2023 Jun; 17(3):606-614. PubMed ID: 36583842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia.
    Katsuyama H; Yanai H; Adachi H; Hakoshima M
    Gastroenterology Res; 2023 Aug; 16(4):240-243. PubMed ID: 37691751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease.
    Shinozaki S; Tahara T; Lefor AK; Ogura M
    Clin Exp Hepatol; 2020 Sep; 6(3):270-274. PubMed ID: 33145434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score.
    Hatanaka T; Kosone T; Saito N; Takakusagi S; Tojima H; Naganuma A; Takagi H; Uraoka T; Kakizaki S
    JGH Open; 2021 Oct; 5(10):1183-1189. PubMed ID: 34622006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study.
    Hatanaka T; Kakizaki S; Saito N; Nakano Y; Nakano S; Hazama Y; Yoshida S; Hachisu Y; Tanaka Y; Kashiwabara K; Yoshinaga T; Tojima H; Naganuma A; Uraoka T
    Intern Med; 2021 Jul; 60(14):2167-2174. PubMed ID: 33612679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage.
    Nomoto H; Kito K; Iesaka H; Handa T; Yanagiya S; Miya A; Kameda H; Cho KY; Takeuchi J; Nagai S; Sakuma I; Nakamura A; Atsumi T
    Diabetol Metab Syndr; 2023 Oct; 15(1):214. PubMed ID: 37880780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
    Yokote K; Yamashita S; Arai H; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Cardiovasc Diabetol; 2021 May; 20(1):96. PubMed ID: 33947390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study.
    Shinozaki S; Tahara T; Miura K; Lefor AK; Yamamoto H
    Life (Basel); 2023 Jun; 13(6):. PubMed ID: 37374110
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients.
    Sugimoto R; Iwasa M; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
    Front Med (Lausanne); 2023; 10():1073025. PubMed ID: 36824614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD.
    Iwadare T; Kimura T; Kunimoto H; Okumura T; Wakabayashi SI; Kobayashi H; Yamashita Y; Sugiura A; Tanaka N; Umemura T
    Front Endocrinol (Lausanne); 2024; 15():1329294. PubMed ID: 38828415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease.
    Ishikawa T; Terai N; Igarashi T; Yamazaki S; Kobayashi T; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Clin Exp Hepatol; 2023 Jun; 9(2):172-178. PubMed ID: 37502434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
    Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S;
    J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up.
    Ikeda S; Sugihara T; Kihara T; Matsuki Y; Nagahara T; Takata T; Kitao S; Okura T; Yamamoto K; Isomoto H
    Diagnostics (Basel); 2021 Dec; 11(12):. PubMed ID: 34943553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance.
    Matsuba I; Matsuba R; Ishibashi S; Yamashita S; Arai H; Yokote K; Suganami H; Araki E
    J Diabetes Investig; 2018 Nov; 9(6):1323-1332. PubMed ID: 29603684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
    Katakura Y; Shimoda M; Ohnishi M; Kusano T; Dan K; Isobe H; Wamata R; Iwamoto Y; Fushimi Y; Sanada J; Obata A; Kimura T; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
    Nutr Metab Cardiovasc Dis; 2023 Jul; 33(7):1444-1452. PubMed ID: 37246074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.